KCNQ3

Summary

KCNQ3 (potassium voltage-gated channel subfamily Q member 3, HGNC:6297) is a protein-coding gene on chromosome 8q24.22, encoding Potassium voltage-gated channel subfamily KQT member 3 (O43525). Pore-forming subunit of the voltage-gated potassium (Kv) M-channel which is responsible for the M-current, a key controller of neuronal excitability.

This gene encodes a protein that functions in the regulation of neuronal excitability. The encoded protein forms an M-channel by associating with the products of the related KCNQ2 or KCNQ5 genes, which both encode integral membrane proteins. M-channel currents are inhibited by M1 muscarinic acetylcholine receptors and are activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 2 (BFNC2), also known as epilepsy, benign neonatal type 2 (EBN2). Alternative splicing of this gene results in multiple transcript variants.

Source: NCBI Gene 3786 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Definitive, ClinGen) — +5 more curated relationships
• GWAS associations: 5
• Clinical variants (ClinVar): 1,489 total — 26 pathogenic, 25 likely-pathogenic
• Phenotypes (HPO): 54
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_004519

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6297
Approved symbol	KCNQ3
Name	potassium voltage-gated channel subfamily Q member 3
Location	8q24.22
Locus type	gene with protein product
Status	Approved
Aliases	Kv7.3
Ensembl gene	ENSG00000184156
Ensembl biotype	protein_coding
OMIM	602232
Entrez	3786

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 4 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000388996, ENST00000519445, ENST00000519589, ENST00000521134, ENST00000638588, ENST00000639358, ENST00000639496

RefSeq mRNA: 2 — MANE Select: NM_004519 NM_001204824, NM_004519

CCDS: CCDS34943, CCDS56554

Canonical transcript exons

ENST00000388996 — 15 exons

Exon	Start	End
ENSE00001292248	132140076	132140178
ENSE00001306403	132480147	132481095
ENSE00001307569	132141129	132141331
ENSE00001327355	132120861	132129996
ENSE00003511798	132175453	132175608
ENSE00003530514	132174239	132174349
ENSE00003534966	132132180	132132264
ENSE00003546076	132184241	132184367
ENSE00003585982	132134290	132134388
ENSE00003591610	132180157	132180329
ENSE00003592914	132137885	132138016
ENSE00003634278	132163468	132163494
ENSE00003663352	132186091	132186181
ENSE00003677885	132172598	132172693
ENSE00003687834	132170334	132170428

Expression profiles

Bgee: expression breadth ubiquitous, 180 present calls, max score 96.26.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4851 / max 49.1324, expressed in 370 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
95055	0.5572	159
95054	0.5294	155
95048	0.3041	132
95049	0.0886	34
95050	0.0058	2

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	96.26	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.24	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.19	gold quality
substantia nigra pars compacta	UBERON:0001965	93.22	gold quality
endothelial cell	CL:0000115	93.00	gold quality
pons	UBERON:0000988	92.93	gold quality
middle temporal gyrus	UBERON:0002771	92.92	gold quality
postcentral gyrus	UBERON:0002581	91.62	gold quality
cortical plate	UBERON:0005343	91.55	gold quality
substantia nigra pars reticulata	UBERON:0001966	91.42	gold quality
parietal lobe	UBERON:0001872	91.24	gold quality
entorhinal cortex	UBERON:0002728	91.07	gold quality
superior frontal gyrus	UBERON:0002661	91.03	gold quality
superior vestibular nucleus	UBERON:0007227	88.34	gold quality
primary visual cortex	UBERON:0002436	88.25	gold quality
occipital lobe	UBERON:0002021	88.12	gold quality
prefrontal cortex	UBERON:0000451	87.44	gold quality
dorsal plus ventral thalamus	UBERON:0001897	86.59	gold quality
temporal lobe	UBERON:0001871	86.07	gold quality
frontal cortex	UBERON:0001870	85.45	gold quality
neocortex	UBERON:0001950	85.32	gold quality
ventral tegmental area	UBERON:0002691	85.32	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	84.89	gold quality
cerebral cortex	UBERON:0000956	84.86	gold quality
nucleus accumbens	UBERON:0001882	84.53	gold quality
telencephalon	UBERON:0001893	84.31	gold quality
cingulate cortex	UBERON:0003027	83.83	gold quality
anterior cingulate cortex	UBERON:0009835	83.66	gold quality
right frontal lobe	UBERON:0002810	83.19	gold quality
caudate nucleus	UBERON:0001873	83.05	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	32.59
E-HCAD-25	yes	15.00
E-ANND-3	yes	8.95

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): REST, SP1

miRNA regulators (miRDB)

329 targeting KCNQ3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4482-3P	99.98	72.50	3147

Literature-anchored findings (GeneRIF, showing 40)

• A cytoplasmic carboxy-terminal subunit interaction domain (sid) suffices to transfer assembly properties between KCNQ3 and KCNQ1. (PMID:12524525)
• specific parts of the C-terminus enable the interaction between KCNQ2 and KCNQ3 channels and that different parts of the KCNQ3 C-terminus are important for regulating current amplitude (PMID:12640002)
• Coexpressed KCNQ2 plus KCNQ3 cDNAs generate channels with 1:1 (KCNQ2:KCNQ3) stoichiometry in CHO cells and that native M channels in SCG neurons adopt the same conformation during development (PMID:12832524)
• There may be a genetic contribution of this gene in juvenile myoclonic epilepsy in a South Indian population. (PMID:12928862)
• Src associates with KCNQ2-5 subunits but phosphorylates only KCNQ3-5. (PMID:15304482)
• After KCNQ2/3 heteromerization, current levels can augment as much as 10-fold, and we have discovered that there are three processes underlying this potentiation. (PMID:15483133)
• the KCNQ2 mutation is responsible for the benign familial neonatal convulsion phenotype, possibly because of haplo-insufficiency, whereas the KCNQ3 variant is functionally silent (PMID:16235065)
• Mutagenesis and electrophysiological studies of the second site, located in the S4-S5 intracellular loop of all KCNQ subunits, reveal a mechanism of channel inhibition (PMID:16319223)
• the diacylglycerol produced during activation of phospholipase c, any activation of protein kinase C that it may stimulate, and downstream products of its metabolism are not essential players in the acute muscarinic modulation of KCNQ2/3 channels (PMID:16721610)
• Several BFNC mutations of KCNQ2 and KCNQ3 disrupt surface expression or polarized surface distribution of KCNQ channels, thereby revealing impaired targeting of KCNQ channels to axonal surfaces as a benign familial neonatal convulsions (BFNC) etiology. (PMID:16735477)
• depletion of phosphatidylinositol 4,5-bisphosphate suffices to suppress KCNQ current fully, and other second messengers are not needed (PMID:16990515)
• ICA-27243 is a novel and selective KCNQ3 potassium channel activator. (PMID:18089837)
• The expression of KCNQ3 increased in late fetal life to infancy in brain. (PMID:18166285)
• This study identified a novel missense mutation of KCNQ3, c.988C>T located within exon 6. c.988C>T led to the substitution Cys for Arg in amino acid position 330 (p.R330C) in KCNQ3 potassium channel. (PMID:18249525)
• A three-dimensional homology model in the W309R mutant indicated that the R side chain of pore helices is too far from the Y side chain of the selectivity filter to interact via hydrogen bonds with each other and stabilize the pore structure. (PMID:18425618)
• Sequence variations of the KCNQ2 (and KCNQ3)genes may contribute to the etiology of common idiopathic epilepsy syndromes. (PMID:18625963)
• among the allowed assembly conformations are KCNQ3/4 and KCNQ4/5 heteromers. (PMID:18786918)
• most wild-type channels are functionally silent, with rearrangements of the pore-loop architecture induced by the presence of a hydroxyl-containing residue at the 315 position “unlocking” the channels into a conductive conformation (PMID:18790849)
• mutations in the SCN1A gene are differentially involved in the pathogenesis of and sequence variations of the KCNQ2 and KCNQ3 genes may contribute to the etiology of rare and common idiopathic epilepsy syndromes [review] (PMID:19464834)
• This study reported that the presence of this uncommon residue at position 315 has a strong impact on the stability of the homotetramers and on channel trafficking. (PMID:20610766)
• Data show that KCNQ3 and KCNE5 mRNA expressions were significantly upregulated in preeclampsia. (PMID:21730298)
• Different structural determinants, identified at the N and C termini of KCNQ3, prevent the effects of syntaxin 1A and calmodulin, respectively. (PMID:21976501)
• constitutive tethering of calmodulin is not required for Kv7 channel function (PMID:21980481)
• the Kv7.2-Kv7.3 heteromer assembles as a tetramer with a predominantly 2:2 subunit stoichiometry and with a random subunit arrangement. (PMID:22334706)
• This study demonistrated that benign neonatal sleep myoclonus can show autosomal dominant inheritance but not allelic to KCNQ3. (PMID:22447848)
• A medium-throughput assay reliably detects changes in the biophysical properties of three classes of KCNQ2/3 channels and peak current amplitude and therefore may serve as a reliable assay to evaluate KCNQ2/3 openers and blockers. (PMID:23002961)
• the single KCNQ channel in Drosophila (dKCNQ) has similar electrophysiological properties to neuronal KCNQ2/3 (PMID:23209695)
• KCNQ3 mutations might be involved in families with infantile seizures. (PMID:23360469)
• We described clinical, genetic, and functional data from 17 families with a diagnosis of benign familial neonatal epilepsy caused by KCNQ2 or KCNQ3 mutations and we showed that some mutations lead to a reduction of Q2 channel regulation by syntaxin-1A. (PMID:24375629)
• We monitored KCNQ2/3 channel currents and translocation of PHPLCdelta1 domains as real-time indicators of PM PI(4,5)P2, and translocation of PHOSH2x2, and PHOSH1 domains as indicators of plasma membrane and Golgi PI(4)P, respectively. (PMID:24843134)
• In bipolar disorder patients’ prefrontal cortex, Kcnq3 expression was decreased, DNA methylation was decreased, and Kcnq3 mRNA was decreased compared to controls. (PMID:25041603)
• the clinical and EEG features of this patient further on expand the phenotypic variability of KCNQ3 gene mutations (PMID:25278462)
• mutations in KCNQ3, similarly to KCNQ2, can be found in patients with more severe phenotypes including intellectual disability (PMID:25524373)
• the present results suggest that gain-of-function mutations in Kv7.2/3 currents may cause human epilepsy with a severe clinical course (PMID:25740509)
• Phosphorylation of KCNQ2 and KCNQ3 anchor domains by protein kinase CK2 augments binding to AnkG. (PMID:25998125)
• a structural mechanism for the gating of the Kv7.3 PM and for the site of action of RTG as a Kv7.2/Kv7.3 K(+) current activator. (PMID:26627826)
• Carboxyl terminus helix C-D linker residues play a role in KCNQ3 current amplitudes by controlling the exit of the KCNQ3 channel from the endoplasmic reticulum. (PMID:26692086)
• Tannic acid activates Kv7.4 and Kv7.3/7.5 K(+) channels resulting in vasodilation. (PMID:26969140)
• USP36 actions extend beyond TrkA because the presence of USP36 interferes with Nedd4-2-dependent Kv7.2/3 channel regulation. (PMID:27445338)
• In the present work, a pharmacophore-based 3D-QSAR model was generated for a series of N-pyridyl and pyrimidine benzamides possessing KCNQ2/Q3 opening activity. The pharmacophore model generated contains one hydrogen bond donor (D), one hydrophobic (H), and two aromatic rings (R). They are the crucial molecular write-up detailing predicted binding efficacy of high affinity and low affinity ligands for KCNQ2/Q3 opening a (PMID:27607834)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	kcnq3	ENSDARG00000060085
mus_musculus	Kcnq3	ENSMUSG00000056258
rattus_norvegicus	Kcnq3	ENSRNOG00000005206

Paralogs (31): KCNG1 (ENSG00000026559), KCNQ1 (ENSG00000053918), KCNQ2 (ENSG00000075043), KCND1 (ENSG00000102057), KCNA7 (ENSG00000104848), KCNA1 (ENSG00000111262), KCNC4 (ENSG00000116396), KCNQ4 (ENSG00000117013), KCNS1 (ENSG00000124134), KCNC1 (ENSG00000129159), KCNA5 (ENSG00000130037), KCNC3 (ENSG00000131398), KCNA10 (ENSG00000143105), KCNA6 (ENSG00000151079), KCNS2 (ENSG00000156486), KCNB1 (ENSG00000158445), KCNF1 (ENSG00000162975), KCNV1 (ENSG00000164794), KCNC2 (ENSG00000166006), KCNV2 (ENSG00000168263), KCNG4 (ENSG00000168418), KCNS3 (ENSG00000170745), KCNG3 (ENSG00000171126), KCND3 (ENSG00000171385), KCNA3 (ENSG00000177272), KCNA2 (ENSG00000177301), KCNG2 (ENSG00000178342), KCNA4 (ENSG00000182255), KCNB2 (ENSG00000182674), KCND2 (ENSG00000184408), KCNQ5 (ENSG00000185760)

Protein

Protein identifiers

Potassium voltage-gated channel subfamily KQT member 3 — O43525 (reviewed: O43525)

Alternative names: KQT-like 3, Potassium channel subunit alpha KvLQT3, Voltage-gated potassium channel subunit Kv7.3

All UniProt accessions (5): A0A1W2PNZ2, A0A1W2PQ71, A0A1W2PRN8, E7ET42, O43525

UniProt curated annotations — full annotation on UniProt →

Function. Pore-forming subunit of the voltage-gated potassium (Kv) M-channel which is responsible for the M-current, a key controller of neuronal excitability. M-channel is composed of pore-forming subunits KCNQ2 and KCNQ3 assembled as heterotetramers. The native M-current has a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. M-channel is selectively permeable in vitro to other cations besides potassium, in decreasing order of affinity K(+) > Rb(+) > Cs(+) > Na(+). M-channel association with SLC5A3/SMIT1 alters channel ion selectivity, increasing Na(+) and Cs(+) permeation relative to K(+). Suppressed by activation of M1 muscarinic acetylcholine receptors. KCNQ3 also associates with KCNQ5 to form a functional channel in vitro and may also contribute to the M-current in brain.

Subunit / interactions. Heterotetramer with KCNQ2; forms heterotetrameric native M-channel responsible for the M-current. Interacts with calmodulin; the interaction is calcium-independent, constitutive and participates in the proper assembly of a functional M-channel. Heteromultimer with KCNQ5. May associate with KCNE2. Interacts with IQCJ-SCHIP1. Interacts (via the pore module) with SLC5A3/SMIT1; forms a coregulatory complex that alters ion selectivity, voltage dependence and gating kinetics of the channel.

Subcellular location. Cell membrane.

Tissue specificity. Predominantly expressed in brain.

Post-translational modifications. KCNQ2/KCNQ3 are ubiquitinated by NEDD4L. Ubiquitination leads to protein degradation. Degradation induced by NEDD4L is inhibited by USP36.

Disease relevance. Seizures, benign familial neonatal 2 (BFNS2) [MIM:121201] A disorder characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset. The disease is caused by variants affecting the gene represented in this entry. Defects in KCNQ3 may be involved in epileptic disorders. These are characterized by paroxysmal transient disturbances of the electrical activity of the brain that may be manifested as episodic impairment or loss of consciousness, abnormal motor phenomena, psychic or sensory disturbances, or perturbation of the autonomic nervous system.

Activity regulation. Phosphatidylinositol-4,5-bisphosphate (PIP2) potentiates the activation of KCNQ channels by enhancing the electro-mechanical coupling of the voltage-sensing domain (VSD) and the pore-forming domain (PD). In the closed state of the channel, PIP2 is anchored at the S2-S3 loop; upon channel activation, PIP2 interacts with the S4-S5 linker and is involved in channel gating. Calcium suppresses KCNQ2-KCNQ3 channel currents, with calcium-bound calmodulin inducing a change in channel configuration which leads to the reduction of channel affinity for PIP2 and subsequent current suppression. M-channel is activated by the anticonvulsant retigabine.

Domain organisation. Each subunit contains six transmembrane segments (S1-S6) with S1-S4 forming one voltage sensing domain (VSD) and S5-S6 contributing to form one quarter of an interlocking pore-forming domain (PD). The S4-S5 linker preferentially interacts with PIP2 in the open-state KCNQ2 channel, whereas the S2-S3 loop interacts with PIP2 in the closed state. The intracellular C-terminal domain is bound constitutively by calmodulin (CaM). This domain plays key functions in channel tetramerization, trafficking, and gating.

Similarity. Belongs to the potassium channel family. KQT (TC 1.A.1.15) subfamily. Kv7.3/KCNQ3 sub-subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
O43525-1	1	yes
O43525-2	2

RefSeq proteins (2): NP_001191753, NP_004510* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003937	K_chnl_volt-dep_KCNQ	Family
IPR003948	K_chnl_volt-dep_KCNQ3	Family
IPR005821	Ion_trans_dom	Domain
IPR013821	K_chnl_volt-dep_KCNQ_C	Domain
IPR020969	Ankyrin-G_BS	Binding_site

Pfam: PF00520, PF03520, PF11956

Catalyzed reactions (Rhea), 4 shown:

• K(+)(in) = K(+)(out) (RHEA:29463)
• Na(+)(in) = Na(+)(out) (RHEA:34963)
• Rb(+)(in) = Rb(+)(out) (RHEA:78547)
• Cs(+)(in) = Cs(+)(out) (RHEA:78555)

UniProt features (47 total): topological domain 8, sequence variant 8, transmembrane region 6, region of interest 4, compositionally biased region 4, binding site 3, mutagenesis site 3, modified residue 2, splice variant 2, sequence conflict 2, helix 2, chain 1, intramembrane region 1, short sequence motif 1

Structure

Experimental structures (PDB)

16 structures.

PDB	Method	Resolution (Å)
5J03	X-RAY DIFFRACTION	2
22BJ	ELECTRON MICROSCOPY	2.4
22BF	ELECTRON MICROSCOPY	2.5
22BG	ELECTRON MICROSCOPY	2.5
22BE	ELECTRON MICROSCOPY	2.6
22BI	ELECTRON MICROSCOPY	2.6
22AZ	ELECTRON MICROSCOPY	2.7
22BK	ELECTRON MICROSCOPY	2.7
22BC	ELECTRON MICROSCOPY	2.8
22BH	ELECTRON MICROSCOPY	2.8
22RJ	ELECTRON MICROSCOPY	2.82
22BA	ELECTRON MICROSCOPY	2.9
22RQ	ELECTRON MICROSCOPY	2.9
22BD	ELECTRON MICROSCOPY	3
9X5J	ELECTRON MICROSCOPY	3.05
9X65	ELECTRON MICROSCOPY	3.19

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43525-F1	57.50	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 243; 259; 366

Post-translational modifications (2): 81, 246

Mutagenesis-validated functional residues (3):

Position	Phenotype
246	no effect on current or expression.
246	abolishes currents without reducing channel protein expression.
318	>50% reduction of wt heteromeric current; ratio of 1:1 and 1:1:2.

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-1296072	Voltage gated Potassium channels
R-HSA-445095	Interaction between L1 and Ankyrins
R-HSA-112316	Neuronal System
R-HSA-1266738	Developmental Biology
R-HSA-1296071	Potassium Channels
R-HSA-373760	L1CAM interactions
R-HSA-422475	Axon guidance
R-HSA-9675108	Nervous system development

MSigDB gene sets: 332 (showing top): GOBP_POTASSIUM_ION_TRANSPORT, GOBP_MEMBRANE_DEPOLARIZATION, BENPORATH_ES_WITH_H3K27ME3, MODULE_274, GOBP_BEHAVIOR, REACTOME_VOLTAGE_GATED_POTASSIUM_CHANNELS, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS, REACTOME_POTASSIUM_CHANNELS, ENK_UV_RESPONSE_KERATINOCYTE_UP, GOBP_NEURON_MATURATION, MODULE_45, MODULE_64, GOBP_PROTEIN_TARGETING, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR

GO Biological Process (34): protein targeting (GO:0006605), protein import into nucleus (GO:0006606), exocytosis (GO:0006887), endocytosis (GO:0006897), chemical synaptic transmission (GO:0007268), sensory perception of sound (GO:0007605), gene expression (GO:0010467), response to auditory stimulus (GO:0010996), neuron remodeling (GO:0016322), neuronal action potential (GO:0019228), nerve development (GO:0021675), psychomotor behavior (GO:0036343), regulation of synaptic plasticity (GO:0048167), neuron apoptotic process (GO:0051402), mitochondrial depolarization (GO:0051882), membrane hyperpolarization (GO:0060081), cellular response to calcium ion (GO:0071277), cellular response to xenobiotic stimulus (GO:0071466), potassium ion transmembrane transport (GO:0071805), apoptosome assembly (GO:0097314), excitatory chemical synaptic transmission (GO:0098976), inhibitory chemical synaptic transmission (GO:0098977), action potential initiation (GO:0099610), regulation of action potential firing threshold (GO:0099611), substantia propria of cornea development (GO:1903701), monoatomic ion transport (GO:0006811), potassium ion transport (GO:0006813), response to mechanical stimulus (GO:0009612), protein transport (GO:0015031), neuron differentiation (GO:0030182), monoatomic ion transmembrane transport (GO:0034220), establishment of localization in cell (GO:0051649), transmembrane transport (GO:0055085), protein-containing complex assembly (GO:0065003)

GO Molecular Function (7): voltage-gated potassium channel activity (GO:0005249), calmodulin binding (GO:0005516), voltage-gated monoatomic cation channel activity (GO:0022843), monoatomic ion channel activity (GO:0005216), voltage-gated monoatomic ion channel activity (GO:0005244), potassium channel activity (GO:0005267), protein binding (GO:0005515)

GO Cellular Component (9): mitochondrion (GO:0005739), plasma membrane (GO:0005886), voltage-gated potassium channel complex (GO:0008076), cell surface (GO:0009986), node of Ranvier (GO:0033268), axon initial segment (GO:0043194), synapse (GO:0045202), membrane (GO:0016020), monoatomic ion channel complex (GO:0034702)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Potassium Channels	1
L1CAM interactions	1
Neuronal System	1
Axon guidance	1
Nervous system development	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
vesicle-mediated transport	2
monoatomic cation channel activity	2
main axon	2
establishment of protein localization	1
intracellular protein transport	1
protein localization to nucleus	1
import into nucleus	1
establishment of protein localization to organelle	1
secretion by cell	1
vesicle fusion to plasma membrane	1
vesicle budding from membrane	1
membrane invagination	1
import into cell	1
anterograde trans-synaptic signaling	1
sensory perception of mechanical stimulus	1
macromolecule biosynthetic process	1
response to mechanical stimulus	1
neuron maturation	1
action potential	1
transmission of nerve impulse	1
nervous system development	1
anatomical structure development	1
motor behavior	1
modulation of chemical synaptic transmission	1
regulation of biological quality	1
apoptotic process	1
mitochondrion	1
regulation of mitochondrial membrane potential	1
membrane depolarization	1
regulation of membrane potential	1
response to calcium ion	1
cellular response to metal ion	1
response to xenobiotic stimulus	1
cellular response to chemical stimulus	1
potassium ion transport	1
monoatomic cation transmembrane transport	1
protein-containing complex assembly	1
apoptotic signaling pathway	1
potassium channel activity	1

Protein interactions and networks

STRING

2622 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KCNQ3	KCNQ5	Q9NR82	984
KCNQ3	KCNQ2	O43526	984
KCNQ3	ANK3	Q12955	883
KCNQ3	KCNE1	P15382	867
KCNQ3	CALM1	P02593	791
KCNQ3	CALML3	P27482	754
KCNQ3	CALML5	Q9NZT1	754
KCNQ3	CALML6	Q8TD86	745
KCNQ3	CALML4	Q96GE6	745
KCNQ3	CHRNA4	P43681	734
KCNQ3	SCN2A	Q99250	724
KCNQ3	SCN1A	P35498	722
KCNQ3	CSTB	P04080	675
KCNQ3	SCN8A	Q9UQD0	667
KCNQ3	KCNT1	Q5JUK3	635

IntAct

2 interactions, top by confidence:

A	B	Type	Score
KCNQ3	AKT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (41): KCNQ2 (Affinity Capture-Western), KCNQ5 (Affinity Capture-Western), KCNQ3 (Affinity Capture-Western), SRXN1 (Affinity Capture-MS), TRAPPC9 (Affinity Capture-MS), TRAPPC4 (Affinity Capture-MS), TRAPPC6B (Affinity Capture-MS), WDR73 (Affinity Capture-MS), TRAPPC10 (Affinity Capture-MS), AKT2 (Affinity Capture-MS), KCNQ3 (Affinity Capture-MS), KCNQ3 (Positive Genetic), KCNQ3 (Affinity Capture-Western), KCNQ2 (Affinity Capture-Western), KCNQ3 (Affinity Capture-Western)

ESM2 similar proteins: A6H8H5, B1WAZ8, O18868, O43525, O43526, O54928, O70344, O75159, O88866, O88943, O88944, O95279, P15385, P15387, P19024, P22462, P51787, P56696, P57058, Q03717, Q14721, Q14B80, Q3UUF8, Q4ZHA6, Q5JV73, Q61762, Q62897, Q63099, Q68UT7, Q76N89, Q8K3F6, Q8K4P8, Q92831, Q92953, Q95167, Q95L11, Q96PR1, Q9JHD1, Q9JK45, Q9JK96

Diamond homologs: A4K2M4, A4K2N8, A4K2P6, A4K2Q6, A4K2R3, A4K2S2, A4K2T1, A4K2V2, A4K2W6, A4K2X4, A4K2Y2, A6H8H5, B2RQA1, G5EFC3, O15554, O18868, O35173, O35174, O43525, O43526, O70344, O73606, O73925, O88758, O88759, O88943, O88944, O89109, O97531, P08510, P0A333, P0A334, P10499, P15384, P15387, P16388, P16389, P16390, P17658, P17659

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
ezogabine	up-regulates	KCNQ3	“chemical activation”
KCNQ3	“up-regulates quantity”	potassium(1+)	relocalization
KCNQ3	“up-regulates activity”	KCNQ2	binding
KCNQ2	“up-regulates activity”	KCNQ3	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

1489 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	26
Likely pathogenic	25
Uncertain significance	731
Likely benign	418
Benign	156

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1071385	NC_000008.10:g.(?133141509)(133492779_?)del	Pathogenic
1334436	NM_004519.4(KCNQ3):c.989G>T (p.Arg330Leu)	Pathogenic
1355934	NM_004519.4(KCNQ3):c.802G>C (p.Gly268Arg)	Pathogenic
1451762	NM_004519.4(KCNQ3):c.1423del (p.Ala475fs)	Pathogenic
1453259	NM_004519.4(KCNQ3):c.1599del (p.Lys533fs)	Pathogenic
1701059	NM_004519.4(KCNQ3):c.509A>G (p.Glu170Gly)	Pathogenic
2009234	NM_004519.4(KCNQ3):c.893del (p.Glu298fs)	Pathogenic
2134180	NM_004519.4(KCNQ3):c.710T>A (p.Met237Lys)	Pathogenic
21415	NM_004519.4(KCNQ3):c.925T>C (p.Trp309Arg)	Pathogenic
2705067	NM_004519.4(KCNQ3):c.299_302del (p.Asn100fs)	Pathogenic
2713298	NM_004519.4(KCNQ3):c.115G>T (p.Glu39Ter)	Pathogenic
2724292	NM_004519.4(KCNQ3):c.1576C>T (p.Gln526Ter)	Pathogenic
3655008	NM_004519.4(KCNQ3):c.958G>A (p.Gly320Arg)	Pathogenic
3725428	NM_004519.4(KCNQ3):c.1048del (p.Ile350fs)	Pathogenic
433110	NM_004519.4(KCNQ3):c.1142C>T (p.Ala381Val)	Pathogenic
449733	NM_004519.4(KCNQ3):c.1060G>A (p.Gly354Arg)	Pathogenic
4719410	NM_004519.4(KCNQ3):c.61_77dup (p.Asn27fs)	Pathogenic
4726206	NM_004519.4(KCNQ3):c.1264C>T (p.Gln422Ter)	Pathogenic
538551	NM_004519.4(KCNQ3):c.1078C>T (p.Gln360Ter)	Pathogenic
566195	NM_004519.4(KCNQ3):c.1685dup (p.Tyr563fs)	Pathogenic
656938	NM_004519.4(KCNQ3):c.1090C>T (p.Arg364Cys)	Pathogenic
7392	NM_004519.4(KCNQ3):c.929G>T (p.Gly310Val)	Pathogenic
839826	NM_004519.4(KCNQ3):c.1220_1221del (p.Ser407fs)	Pathogenic
841488	NM_004519.4(KCNQ3):c.1722del (p.Gly575fs)	Pathogenic
842150	NM_004519.4(KCNQ3):c.61_77del (p.Gly20_Gly21insTer)	Pathogenic
978934	NM_004519.4(KCNQ3):c.688C>A (p.Arg230Ser)	Pathogenic
1012603	NM_004519.4(KCNQ3):c.938C>T (p.Thr313Ile)	Likely pathogenic
1067197	NM_004519.4(KCNQ3):c.929G>A (p.Gly310Asp)	Likely pathogenic
1067624	NM_004519.4(KCNQ3):c.1123G>A (p.Ala375Thr)	Likely pathogenic
1176275	NM_004519.4(KCNQ3):c.933G>A (p.Leu311=)	Likely pathogenic

SpliceAI

4775 predictions. Top by Δscore:

Variant	Effect	Δscore
8:132129992:TGAAC:T	acceptor_gain	1.0000
8:132129993:GAAC:G	acceptor_gain	1.0000
8:132129995:AC:A	acceptor_gain	1.0000
8:132129996:CC:C	acceptor_gain	1.0000
8:132129997:C:CC	acceptor_gain	1.0000
8:132132173:GACTT:G	donor_loss	1.0000
8:132132174:ACTTA:A	donor_loss	1.0000
8:132132175:CTTAC:C	donor_loss	1.0000
8:132132176:TTA:T	donor_loss	1.0000
8:132132177:TA:T	donor_loss	1.0000
8:132132178:ACCT:A	donor_loss	1.0000
8:132132179:C:CT	donor_loss	1.0000
8:132132179:CCTGT:C	donor_gain	1.0000
8:132132263:TCC:T	acceptor_loss	1.0000
8:132132265:C:CA	acceptor_loss	1.0000
8:132132266:T:C	acceptor_loss	1.0000
8:132140070:CATTA:C	donor_loss	1.0000
8:132140072:TTA:T	donor_loss	1.0000
8:132140073:TACCT:T	donor_loss	1.0000
8:132141123:CATTA:C	donor_loss	1.0000
8:132141124:ATTAC:A	donor_loss	1.0000
8:132141125:TTA:T	donor_loss	1.0000
8:132141126:TACC:T	donor_loss	1.0000
8:132141127:ACCT:A	donor_loss	1.0000
8:132141128:C:G	donor_loss	1.0000
8:132163466:A:AC	donor_gain	1.0000
8:132163467:C:CC	donor_gain	1.0000
8:132172690:TGCC:T	acceptor_gain	1.0000
8:132172692:CC:C	acceptor_gain	1.0000
8:132172692:CCCTG:C	acceptor_loss	1.0000

AlphaMissense

5657 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:132137894:A:G	L564P	1.000
8:132137912:A:G	L558P	1.000
8:132137921:A:G	L555P	1.000
8:132137925:G:C	H554D	1.000
8:132137928:C:G	G553R	1.000
8:132137928:C:T	G553R	1.000
8:132137937:A:G	Y550H	1.000
8:132137945:A:T	I547N	1.000
8:132137984:A:G	F534S	1.000
8:132170374:A:G	W399R	1.000
8:132170374:A:T	W399R	1.000
8:132170422:A:G	W383R	1.000
8:132170422:A:T	W383R	1.000
8:132172605:A:G	L378P	1.000
8:132172614:G:T	A375D	1.000
8:132172634:A:C	F368L	1.000
8:132172634:A:T	F368L	1.000
8:132172636:A:G	F368L	1.000
8:132172639:G:C	H367D	1.000
8:132172647:C:G	R364P	1.000
8:132172648:G:T	R364S	1.000
8:132172668:A:G	L357P	1.000
8:132172668:A:T	L357H	1.000
8:132172671:G:T	A356D	1.000
8:132172683:C:T	G352E	1.000
8:132172684:C:A	G352W	1.000
8:132172684:C:G	G352R	1.000
8:132172684:C:T	G352R	1.000
8:132172692:C:T	G349D	1.000
8:132172693:C:G	G349R	1.000

dbSNP variants (sampled 300 via entrez): RS1000017239 (8:132397063 T>C), RS1000022543 (8:132241419 C>T), RS1000022761 (8:132392022 A>G), RS1000026151 (8:132357185 T>C), RS1000030581 (8:132226867 A>G), RS1000043380 (8:132412782 T>A), RS1000044089 (8:132432590 C>T), RS1000052359 (8:132314975 A>G), RS1000070316 (8:132185955 C>G), RS1000083910 (8:132351464 G>C), RS1000088858 (8:132179664 C>A), RS1000099645 (8:132471045 T>G), RS1000106702 (8:132242332 G>A,T), RS1000111675 (8:132412375 C>T), RS1000114395 (8:132478989 G>A,T)

Disease associations

OMIM: gene MIM:602232 | disease phenotypes: MIM:121200, MIM:121201, MIM:617080, MIM:606369, MIM:117100

GenCC curated gene-disease

Disease	Classification	Inheritance
seizures, benign familial neonatal, 2	Strong	Autosomal dominant
benign neonatal seizures	Supportive	Autosomal dominant
benign familial infantile epilepsy	Supportive	Autosomal dominant
genetic developmental and epileptic encephalopathy	Limited	Autosomal recessive

ClinGen Gene-Disease Validity (3)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Definitive	AD
genetic developmental and epileptic encephalopathy	Limited	AR
self-limited familial neonatal epilepsy	Moderate	AD

Mondo (11): benign neonatal seizures (MONDO:0016027), seizures, benign familial neonatal, 2 (MONDO:0007366), prostate cancer (MONDO:0008315), intellectual disability (MONDO:0001071), seizures, benign familial infantile, 5 (MONDO:0014903), Lennox-Gastaut syndrome (MONDO:0016532), neurodevelopmental disorder (MONDO:0700092), self-limited epilepsy with centrotemporal spikes (MONDO:0007295), autism spectrum disorder (MONDO:0005258), genetic developmental and epileptic encephalopathy (MONDO:0100062), benign familial infantile epilepsy (MONDO:0017615)

Orphanet (7): Self-limited neonatal epilepsy (Orphanet:1949), Familial prostate cancer (Orphanet:1331), Lennox-Gastaut syndrome (Orphanet:2382), Self-limited infantile epilepsy (Orphanet:306), Self-limited epilepsy with centrotemporal spikes (Orphanet:1945), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

54 total (30 of 54 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000153	Abnormality of the mouth
HP:0000496	Abnormality of eye movement
HP:0000718	Aggressive behavior
HP:0000961	Cyanosis
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001263	Global developmental delay
HP:0001266	Choreoathetosis
HP:0001276	Hypertonia
HP:0001332	Dystonia
HP:0002020	Gastroesophageal reflux
HP:0002069	Bilateral tonic-clonic seizure
HP:0002072	Chorea
HP:0002104	Apnea
HP:0002121	Generalized non-motor (absence) seizure
HP:0002133	Status epilepticus
HP:0002169	Clonus
HP:0002197	Generalized-onset seizure
HP:0002266	Focal clonic seizure
HP:0002305	Athetosis
HP:0002361	Psychomotor deterioration
HP:0002372	Normal interictal EEG
HP:0002373	Febrile seizure (within the age range of 3 months to 6 years)
HP:0002384	Focal impaired awareness seizure
HP:0002392	EEG with polyspike wave complexes
HP:0003623	Neonatal onset
HP:0004305	Involuntary movements
HP:0007000	Morning myoclonic jerks
HP:0007166	Paroxysmal dyskinesia

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002097_19	Coronary artery calcification	8.000000e-06
GCST002989_8	LDL peak particle diameter (total fat intake interaction)	1.000000e-06
GCST005171_3	QT interval	2.000000e-06
GCST008163_572	Height	2.000000e-06
GCST008464_4	Type 2 diabetes	3.000000e-08

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004723	coronary artery calcification
EFO:0007677	LDL peak particle diameter measurement
EFO:0007678	total fat intake measurement
EFO:0004682	QT interval

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065768	Lennox Gastaut Syndrome	C10.228.140.490.493.750; C16.320.495
D065886	Neurodevelopmental Disorders	F03.625
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (6): CHEMBL2221348 (PROTEIN COMPLEX), CHEMBL2362996 (PROTEIN FAMILY), CHEMBL2363063 (PROTEIN FAMILY), CHEMBL2684 (SINGLE PROTEIN), CHEMBL3707192 (PROTEIN COMPLEX), CHEMBL3883311 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 9,776 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL255044	FLUPIRTINE	4	5,706
CHEMBL41355	EZOGABINE	4	3,996
CHEMBL266510	FLINDOKALNER	3	74

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs7818112	KCNQ3		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: vgic — Voltage-gated potassium channels (K_v)

Most potent curated ligand interactions (5 total), top 5:

Ligand	Action	Affinity	Parameter
gabapentin	Activation	8.28	pEC50
retigabine	Activator	6.2	pEC50
JNJ-37822681	Activation	5.7	pEC50
linopirdine	Inhibitor	5.4	pIC50
tetraethylammonium	Channel blocker	1.5	pIC50

Binding affinities (BindingDB)

13 measured of 15 human assays (15 total across all organisms); most potent 13 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL598553	EC50	21 nM
CHEMBL599164	EC50	25 nM
CHEMBL598126	EC50	27 nM
CHEMBL604937	EC50	28 nM
CHEMBL599781	EC50	53 nM
CHEMBL596909	EC50	91 nM
CHEMBL591203	EC50	98 nM
CHEMBL603662	EC50	160 nM
CHEMBL599365	EC50	160 nM
CHEMBL603661	EC50	380 nM
CHEMBL597329	EC50	570 nM
CHEMBL603667	EC50	2080 nM
CHEMBL603874	EC50	2700 nM

ChEMBL bioactivities

223 potent at pChembl≥5 of 241 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.82	Ki	0.15	nM	CHEMBL5722941
9.74	IC50	0.18	nM	CHEMBL5722941
8.85	EC50	1.4	nM	CHEMBL6147947
8.25	EC50	5.623	nM	CHEMBL6148875
8.19	EC50	6.457	nM	CHEMBL6170048
8.02	EC50	9.55	nM	CHEMBL6143552
8.01	EC50	9.8	nM	CHEMBL5412763
8.00	EC50	10	nM	CHEMBL2047506
7.96	EC50	10.96	nM	CHEMBL6151161
7.95	EC50	11.22	nM	CHEMBL6162279
7.92	EC50	12	nM	CHEMBL6151161
7.92	EC50	12.02	nM	CHEMBL6151161
7.87	EC50	13.49	nM	CHEMBL6143040
7.77	EC50	17	nM	CHEMBL6150442
7.77	EC50	16.98	nM	CHEMBL6150442
7.75	EC50	18	nM	CHEMBL4458793
7.73	EC50	18.62	nM	CHEMBL6150563
7.73	EC50	18.62	nM	CHEMBL6164400
7.70	EC50	20	nM	CHEMBL4278049
7.68	EC50	21	nM	CHEMBL598553
7.64	EC50	23	nM	CHEMBL592297
7.62	EC50	24	nM	CHEMBL3621438
7.60	EC50	25	nM	CHEMBL599164
7.57	EC50	26.92	nM	CHEMBL6145412
7.57	EC50	27	nM	CHEMBL598126
7.55	EC50	28.18	nM	CHEMBL6150442
7.55	EC50	28	nM	CHEMBL604937
7.55	EC50	28	nM	CHEMBL599374
7.54	EC50	29	nM	CHEMBL589898
7.52	EC50	30	nM	CHEMBL2047511
7.43	EC50	37	nM	CHEMBL4093377
7.43	EC50	37	nM	CHEMBL4062193
7.42	EC50	38.02	nM	CHEMBL6144404
7.42	EC50	38.02	nM	CHEMBL6171400
7.40	EC50	40	nM	CHEMBL3621449
7.40	EC50	40	nM	CHEMBL4276984
7.40	EC50	40	nM	CHEMBL1703636
7.36	EC50	44	nM	CHEMBL609624
7.36	EC50	44	nM	CHEMBL591302
7.34	EC50	45.71	nM	CHEMBL6141883
7.31	EC50	49	nM	CHEMBL599376
7.30	EC50	50	nM	CHEMBL3621439
7.30	EC50	50	nM	CHEMBL4277250
7.30	EC50	50	nM	CHEMBL4549421
7.30	EC50	50	nM	CHEMBL4516269
7.28	EC50	52.48	nM	CHEMBL6168436
7.28	EC50	53	nM	CHEMBL599781
7.22	EC50	60	nM	CHEMBL5204124
7.22	EC50	60	nM	CHEMBL1689654
7.21	EC50	62	nM	CHEMBL3621440

PubChem BioAssay actives

183 with measured affinity, of 466 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-[(1R,2aS,4S,5aS,8aS,10S,11aR,14aS,16S,17aS,19S,20aS,22S,23aS,25S,26aS,28S,29aS,31R,32aS,35aS,36R,38aS,39S,41aS,42S,44aS,45S,48R,50aS,51S,53aS,54S,56aS,57S,59aS,60S,63S,66S,69S,72S,75S,78S,87R,93S,96S,99S)-17a,20a,23a,53a,63-pentakis(4-aminobutyl)-31-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-carbamimidamido-2-[[(2S)-5-carbamimidamido-2-[[(2S)-1-[(2S)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-16,29a,72,78-tetrakis(2-amino-2-oxoethyl)-14a,26a-bis(3-amino-3-oxopropyl)-2a,38a,66-tribenzyl-28,50a,57-tris[(2S)-butan-2-yl]-4,5a,19,42,45,69-hexakis(3-carbamimidamidopropyl)-51,54-bis(2-carboxyethyl)-56a,99-bis(carboxymethyl)-36-[[(2S,3S)-1-(carboxymethylamino)-3-methyl-1-oxopentan-2-yl]carbamoyl]-39,60-bis[(1R)-1-hydroxyethyl]-75,93-bis(hydroxymethyl)-32a,35a,59a-tris[(4-hydroxyphenyl)methyl]-22-(1H-imidazol-4-ylmethyl)-96-(1H-indol-3-ylmethyl)-41a-methyl-25-(2-methylpropyl)-1a,3,4a,6,7a,9,10a,13a,15,16a,18,19a,21,22a,24,25a,27,28a,30,31a,34a,37a,38,40a,41,43a,44,47,49a,50,52a,53,55a,56,58a,59,61a,62,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-33,34,63a,64a,67a,68a-hexathia-a,2,3a,5,6a,8,9a,12a,14,15a,17,18a,20,21a,23,24a,26,27a,29,30a,33a,36a,37,39a,40,42a,43,46,48a,49,51a,52,54a,55,57a,58,60a,61,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazapentacyclo[85.74.4.448,111.010,14.0144,148]nonahexacontahectan-8a-yl]propanoic acid	2198828: Binding affinity to KV channel (unknown origin) assessed as inhibition constant	ki	0.0001	uM
N-[4-(2-bromo-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide	2030288: Agonist activity at Kv7.2/Kv7.3 (unknown origin) expressed in human HEK293 cells by whole cell patch clamp assay	ec50	0.0098	uM
N-(6-chloro-3-pyridinyl)-4-phenoxybenzamide	669435: Agonist activity at KCNQ2/KCNQ3 expressed in CHO cells assessed as increase in KCl-induced 86Rb+ efflux incubated for 10 mins prior to KCl-induction by liquid scintillation counting	ec50	0.0100	uM
cyclopropyl N-[2-amino-3-fluoro-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate	1861512: Agonist activity at Kv7.2/3 (unknown origin) expressed in CHO cells co-expressing GFP	ec50	0.0180	uM
N-[(1R)-2-hydroxy-1-(3-methylsulfonylphenyl)ethyl]-5-(pentafluoro-lambda6-sulfanyl)-2-phenoxybenzamide	1414246: Activation of human Kv7.2/7.3 by patch clamp method	ec50	0.0200	uM
N-[(Z)-(5,6-difluoro-3-methyl-1,3-benzothiazol-2-ylidene)amino]adamantane-1-carboxamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0210	uM
tert-butyl N-[(Z)-[3-methyl-6-(trifluoromethoxy)-1,3-benzothiazol-2-ylidene]amino]carbamate	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0230	uM
N-(4,6-dimethoxy-2-thiomorpholin-4-ylpyrimidin-5-yl)-3,3-dimethylbutanamide	1249421: Activation of human Kv7.2/7.3 expressed in CHOK1 cells	ec50	0.0240	uM
N-[(Z)-[3-methyl-6-(trifluoromethoxy)-1,3-benzothiazol-2-ylidene]amino]adamantane-1-carboxamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0250	uM
N-[(Z)-(3-methyl-1,3-benzothiazol-2-ylidene)amino]adamantane-1-carboxamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0270	uM
N-[(Z)-(6-fluoro-3-methyl-1,3-benzothiazol-2-ylidene)amino]adamantane-1-carboxamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0280	uM
N-[(Z)-[3-methyl-6-(trifluoromethoxy)-1,3-benzothiazol-2-ylidene]amino]cyclohexanecarboxamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0280	uM
cyclopentyl N-[(Z)-[3-methyl-6-(trifluoromethoxy)-1,3-benzothiazol-2-ylidene]amino]carbamate	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0290	uM
N-(6-chloro-3-pyridinyl)-3-fluoro-4-phenoxybenzamide	669435: Agonist activity at KCNQ2/KCNQ3 expressed in CHO cells assessed as increase in KCl-induced 86Rb+ efflux incubated for 10 mins prior to KCl-induction by liquid scintillation counting	ec50	0.0300	uM
N-(3,4-difluorophenyl)-6-(trifluoromethoxy)-1H-pyrazolo[4,3-b]pyridin-3-amine	1454473: Activation of KCNQ2/3 (unknown origin)	ec50	0.0370	uM
N-(6-chloro-3-pyridinyl)-6-(trifluoromethyl)-1H-indazol-3-amine	1454473: Activation of KCNQ2/3 (unknown origin)	ec50	0.0370	uM
3-cyclopentyl-N-[4,6-dimethoxy-2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl]propanamide	1249421: Activation of human Kv7.2/7.3 expressed in CHOK1 cells	ec50	0.0400	uM
N-[(1S)-1-(3-methylsulfonylphenyl)ethyl]-2-phenoxy-5-(trifluoromethyl)benzamide	1414246: Activation of human Kv7.2/7.3 by patch clamp method	ec50	0.0400	uM
N-(2,4,6-trimethylphenyl)bicyclo[2.2.1]heptane-2-carboxamide	1414246: Activation of human Kv7.2/7.3 by patch clamp method	ec50	0.0400	uM
2-cyclopentyl-N-[(Z)-[3-methyl-6-(trifluoromethoxy)-1,3-benzothiazol-2-ylidene]amino]acetamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0440	uM
4-fluoro-N-[(Z)-[3-methyl-6-(trifluoromethoxy)-1,3-benzothiazol-2-ylidene]amino]benzamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0440	uM
3,3-dimethyl-N-[(Z)-[3-methyl-6-(trifluoromethoxy)-1,3-benzothiazol-2-ylidene]amino]butanamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0490	uM
N-[2-(4,4-difluoropiperidin-1-yl)-4,6-dimethoxypyrimidin-5-yl]-3,3-dimethylbutanamide	1249421: Activation of human Kv7.2/7.3 expressed in CHOK1 cells	ec50	0.0500	uM
trans-(1S,2S)-5,5-difluoro-N-[(1R)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]-2-phenylcyclohexane-1-carboxamide	1414246: Activation of human Kv7.2/7.3 by patch clamp method	ec50	0.0500	uM
3-cyclopentyl-N-[3-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-2-yl]propanamide	1557153: Agonist activity at human KCNQ2/3 expressed in HEK293 cells by FLIPR based thallium influx assay	ec50	0.0500	uM
N-[3-(4-fluoro-3-methylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl]-3,3-dimethylbutanamide	1557153: Agonist activity at human KCNQ2/3 expressed in HEK293 cells by FLIPR based thallium influx assay	ec50	0.0500	uM
N-[(Z)-[3-methyl-5-(trifluoromethyl)-1,3-benzothiazol-2-ylidene]amino]adamantane-1-carboxamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0530	uM
N-[2-amino-3-fluoro-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]-3,3-dimethylbutanamide	1874639: Activation of Kv7.2/Kv7.3 channel (unknown origin) expressed in CHO cells assessed as maximum current density measured after 24 hrs by whole cell patch clamp based electrophysiological method	ec50	0.0600	uM
5-(2,6-dichloro-5-fluoro-3-pyridinyl)-3-phenyl-2-(trifluoromethyl)-1H-pyrazolo[1,5-a]pyrimidin-7-one	587711: Activation of KCNQ2/Q3 expressed in CHO cells by atomic absorption Rb’+ efflux assay	ec50	0.0600	uM
N-[4,6-dimethoxy-2-(1,4-oxazepan-4-yl)pyrimidin-5-yl]-3,3-dimethylbutanamide	1249421: Activation of human Kv7.2/7.3 expressed in CHOK1 cells	ec50	0.0620	uM
N-[(Z)-[3-methyl-6-(trifluoromethoxy)-1,3-benzothiazol-2-ylidene]amino]cyclopentanecarboxamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0620	uM
N-(4,6-dimethoxy-2-piperidin-1-ylpyrimidin-5-yl)-3,3-dimethylbutanamide	1249421: Activation of human Kv7.2/7.3 expressed in CHOK1 cells	ec50	0.0640	uM
2-cyclopentyl-N-[3-(4-fluoro-3-methylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl]acetamide	1557153: Agonist activity at human KCNQ2/3 expressed in HEK293 cells by FLIPR based thallium influx assay	ec50	0.0700	uM
3-cyclopentyl-N-[3-(4-fluoro-3-methylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl]propanamide	1557153: Agonist activity at human KCNQ2/3 expressed in HEK293 cells by FLIPR based thallium influx assay	ec50	0.0700	uM
N-(6-chloro-3-pyridinyl)-3-fluoro-4-(4-fluorophenyl)sulfonylbenzamide	669435: Agonist activity at KCNQ2/KCNQ3 expressed in CHO cells assessed as increase in KCl-induced 86Rb+ efflux incubated for 10 mins prior to KCl-induction by liquid scintillation counting	ec50	0.0700	uM
N-[(3-methylsulfonylphenyl)methyl]-5-(pentafluoro-lambda6-sulfanyl)-2-phenoxybenzamide	1414246: Activation of human Kv7.2/7.3 by patch clamp method	ec50	0.0800	uM
N-[(1R)-2-hydroxy-1-(3-methylsulfonylphenyl)ethyl]-2-phenoxy-5-(trifluoromethyl)benzamide	1414246: Activation of human Kv7.2/7.3 by patch clamp method	ec50	0.0800	uM
3-cyclopentyl-N-[3-(4-fluoro-3-methylphenyl)-6-methylpyrazolo[1,5-a]pyrimidin-2-yl]propanamide	1557153: Agonist activity at human KCNQ2/3 expressed in HEK293 cells by FLIPR based thallium influx assay	ec50	0.0800	uM
N-(6-chloro-3-pyridinyl)-3-fluoro-4-(4-fluorophenyl)sulfanylbenzamide	669435: Agonist activity at KCNQ2/KCNQ3 expressed in CHO cells assessed as increase in KCl-induced 86Rb+ efflux incubated for 10 mins prior to KCl-induction by liquid scintillation counting	ec50	0.0800	uM
4-chloro-N-(6-chloro-3-pyridinyl)-3-fluorobenzamide	669435: Agonist activity at KCNQ2/KCNQ3 expressed in CHO cells assessed as increase in KCl-induced 86Rb+ efflux incubated for 10 mins prior to KCl-induction by liquid scintillation counting	ec50	0.0800	uM
N-[(Z)-[3-methyl-4-(trifluoromethyl)-1,3-benzothiazol-2-ylidene]amino]adamantane-1-carboxamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0910	uM
propan-2-yl N-[(Z)-[3-methyl-6-(trifluoromethoxy)-1,3-benzothiazol-2-ylidene]amino]carbamate	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0950	uM
N-[(Z)-(7-fluoro-3-methyl-1,3-benzothiazol-2-ylidene)amino]adamantane-1-carboxamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.0980	uM
trans-(1S,2S)-N-[(1R)-1-(3-chlorophenyl)-2-hydroxyethyl]-5,5-difluoro-2-phenylcyclohexane-1-carboxamide	1414246: Activation of human Kv7.2/7.3 by patch clamp method	ec50	0.1000	uM
3-fluoro-N-[(Z)-[3-methyl-6-(trifluoromethoxy)-1,3-benzothiazol-2-ylidene]amino]benzamide	461899: Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	ec50	0.1000	uM
2-cyclopentyl-N-[3-[(4-fluorophenyl)methyl]-6-methylpyrazolo[1,5-a]pyrimidin-2-yl]acetamide	689724: Activation of KCNQ2/Q3	ec50	0.1000	uM
N-[2-(3,3-difluoroazetidin-1-yl)-4,6-dimethoxypyrimidin-5-yl]-3,3-dimethylbutanamide	1249421: Activation of human Kv7.2/7.3 expressed in CHOK1 cells	ec50	0.1100	uM
N-(6-chloro-3-pyridinyl)-3-fluoro-4-propan-2-ylsulfanylbenzamide	669435: Agonist activity at KCNQ2/KCNQ3 expressed in CHO cells assessed as increase in KCl-induced 86Rb+ efflux incubated for 10 mins prior to KCl-induction by liquid scintillation counting	ec50	0.1100	uM
(2S)-2-phenyl-N-(2-pyrrolidin-1-ylphenyl)butanamide	697779: Antagonist activity at KCNQ2/Q3 expressed in CHO cells incubated for 3 mins by automated patch clamp assay	ic50	0.1200	uM
4,5-difluoro-N-[(1S)-1-(3-methylsulfonylphenyl)ethyl]-2-phenoxybenzamide	1414246: Activation of human Kv7.2/7.3 by patch clamp method	ec50	0.1300	uM

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, increases methylation	2
Aflatoxin B1	decreases methylation, increases methylation	2
2,5,2’,5’-tetrachlorobiphenyl	increases expression, decreases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
sulforaphane	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
CGP 52608	increases reaction, affects binding	1
perfluoro-n-nonanoic acid	increases expression	1
ezogabine	decreases response to substance, affects activity	1
N-(1-(3-morpholin-4-ylphenyl)ethyl)-3-phenylacrylamide	affects activity, affects binding	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Arsenic	affects methylation	1
Benzimidazoles	affects binding, increases activity, increases import	1
Cisplatin	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Histamine	affects cotreatment, decreases activity, decreases reaction	1
Methapyrilene	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Thallium	affects binding, increases activity, increases import	1
Triclosan	decreases expression	1
Valproic Acid	increases expression	1
Vanadium	increases expression	1
Cyclosporine	decreases methylation	1
Astemizole	affects cotreatment, decreases activity, decreases reaction	1

ChEMBL screening assays

97 unique, capped per target: 91 binding, 4 functional, 1 admet, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1070909	Binding	Activation of KCNQ2/KCNQ3 expressed in CHO cells by isotopic efflux assay	Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain. — J Med Chem
CHEMBL2050726	Functional	Agonist activity at KCNQ2/KCNQ3 expressed in CHO cells assessed as increase in KCl-induced 86Rb+ efflux incubated for 10 mins prior to KCl-induction by liquid scintillation counting	N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. — ACS Med Chem Lett
CHEMBL4385400	ADMET	Agonist activity at KCNQ2/KCNQ3 (unknown origin) expressed in CHOK1 cells assessed as increase in amplitude of outward current at 10 uM by whole cell patch clamp assay relative to control	Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity. — ACS Med Chem Lett

Cellosaurus cell lines

5 cell lines: 2 induced pluripotent stem cell, 2 spontaneously immortalized cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A6XR	UNINAi001-A	Induced pluripotent stem cell	Male
CVCL_A6XS	UNINAi001-B	Induced pluripotent stem cell	Male
CVCL_C0Y7	B’SYS CHO Kv7.2/3	Spontaneously immortalized cell line	Female
CVCL_D1KA	PrecisION hKv7.2/Kv7.3-CHO	Spontaneously immortalized cell line	Female
CVCL_D1KB	PrecisION hKv7.3/Kv7.5-HEK	Transformed cell line	Female

Clinical trials (associated diseases)

312 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer